In the crinecerfont group, 74% achieved normal A4 levels versus 12% of placebo recipients. Previously reported results in kids showed a benefit for lowering glucocorticoid dose as well.

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont).

ORLANDO — In patients with classic congenital adrenal hyperplasia, crinecerfont conferred meaningful reductions in glucocorticoid dose and androstenedione level in children and improved ...

Although detailed results on crinecerfont’s early testing are limited, this stage is critical. Out of every 5,000 to 10,000 potential new drugs, only one or so make it through the approval process.

Neurocrine Biosciences’ US FDA approved crinecerfont is available for children and adults to treat classic congenital adrenal hyperplasia San Diego Tuesday, December 24, 2024, 09:00 Hrs [IST] ...

Neurocrine Biosciences, Inc, a leading neuroscience-focused, biopharmaceutical company with a simple purpose to relieve suffering for people with great needs and but few options, has announced ...

Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess adrenocorticotropic hormone, said developer Neurocrine Biosciences.

The analyst from H.C. Wainwright has factored crinecerfont into their valuation of Neurocrine for some time. With the approval now official, the firm projects conservative initial sales of $16 million ...

Neurocrine Biosciences announced that the FDA has approved crinecerfont as an adjunct to glucocorticoid replacement to control androgens for patients with congenital adrenal hyperplasia ...